Both public and private payers use cost containment policies to control the amount and mix of drugs included under the prescription drug benefit, which may be administered by a pharmacy benefit manager, or PBM
[1] It represents a novel class of medication as the first dual incretin receptor agonist, activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The peptide is also unusually stable in stomach acid for a peptide, so an oral capsule format exists and is sometimes used in gut-focused research planning
Body skin is generally thicker and less sensitive than facial skin, potentially tolerating higher concentrations
3 Discovery of GLP-1 In 1923, Charles Kimball and John Murlin, in an attempt to purify commercial insulin, precipitated a pancreatic fraction that had a hyperglycemic effect (8)